SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure is experiencing intense investor interest driven by a $400 million convertible note offering and persistent speculation surrounding a potential data center lease with Amazon Web Services at its Moses Lake facility. While some community members warn of potential dilution and volatility, bullish investors view the capital raise as a strategic move to fund aggressive infrastructure expansion and secure major hyperscaler contracts.

Solidion Technology, Inc. engages in researching, developing and manufacturing battery components and materials, batteries and related energy storage products for the automotive electric vehicle and other markets. The company was founded on June 30, 2023 and is headquartered in Dallas, TX.

Solidion Technology Inc

Solidion Technology Inc. is trending as investors weigh its recent patent announcements in the space and AI-battery sectors against concerns regarding limited cash reserves and the potential for future equity dilution. The community is deeply divided, with bulls targeting a short squeeze driven by low float and high borrow rates, while bears caution against a lack of immediate commercial product and the risk of financing-related sell-offs.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending amid a sharp sell-off in the semiconductor sector, fueled by investor anxiety over rising interest rates, strong job data, and profit-taking after a period of intense growth. Community sentiment is deeply polarized, with many retail traders debating whether this volatility represents a healthy buying opportunity for the AI super-cycle or a catastrophic bubble burst that threatens heavily leveraged positions.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending as investors aggressively hunt for exposure to the space economy, specifically tracking its role in Earth imaging and its proximity to upcoming major industry catalysts. The community is actively debating the company's valuation against its long-term strategic moat in sovereign data, with many viewing recent volatility as an accumulation opportunity while institutional interest in the sector continues to rise.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant momentum driven by growing recognition of its QNX software as the critical 'nervous system' for the physical AI and robotics revolution. The community is buzzing over increased institutional interest and a series of strategic partnerships with major tech players, fueling bullish sentiment around the company's long-term potential in edge computing and autonomous systems.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is under intense scrutiny as investors weigh the impact of upcoming IPOs like SpaceX and the influence of new market structure regulations on trading volatility. While some community members remain optimistic about institutional growth and the platform's technological evolution, sentiment is divided as traders debate the sustainability of current valuations and broader macroeconomic pressures.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as the company prepares for its historic NYSE uplisting, a major milestone that has the community buzzing about institutional adoption and potential price re-rating. Investors are actively discussing the significance of Trulieve becoming the first plant-touching operator to list on a major U.S. exchange, sparking widespread debate about whether this catalyst will trigger a sector-wide rally or lead to a sell-the-news event.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense selling pressure and market skepticism as investors weigh macroeconomic concerns and regulatory uncertainty against the project's long-term utility in real-world asset tokenization. While some in the community view these low prices as a generational buying opportunity for the next market cycle, many are frustrated by the token's persistent underperformance and lack of price stability.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors digest pivotal Phase 3 clinical data for its triple-agonist candidate, retatrutide, which has demonstrated significant weight-loss efficacy and bolstered confidence in the company's long-term pipeline. Community discussion is heavily focused on the drug's potential to redefine standards in the obesity and metabolic health sectors, while broader market sentiment highlights Eli Lilly as a defensive leader amid ongoing sector rotation.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is facing significant volatility driven by the conflict in the Middle East, which has sparked investor anxiety regarding jet fuel costs and the stability of commercial aviation. Despite this, the community remains heavily focused on the company's strong SMR pipeline, ongoing share buybacks, and defense contracts, with many seeing the current price swings as a temporary hurdle rather than a shift in long-term fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +30.31% and +73.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates

ANI (ANIP) delivered earnings and revenue surprises of +30.43% and +12.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$3.39	--	--	N/A
Q1 '26	-$2.85	-$4.31	-51.23%	MISSED
Q4 '25	-$6.11	-$3.84	37.12%	BEAT
Q3 '25	-$5.68	-$3.72	34.46%	BEAT
Q2 '25	-$6.30	-$4.46	29.21%	BEAT

BOLTBolt Biotherapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest BOLT News